The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Investment in marketable securities | 0 | 0 |
| Proceeds from disposition of marketable securities | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 |
| Gain on marketable securities | 0 | 0 |
| Change in fair value of marketable securities | 0 | 0 |
| Accrued interest settled with common stock | 0 | 0 |
| Loss on settlement of convertible debt | 0 | 0 |
| Accrued interest income | 0 | 0 |
| Accounts payable and accrued expenses - related parties | 0 | 0 |
| Accrued interest payable | 0 | 0 |
| Net loss | -2,347,302 | -6,759,472 |
| Depreciation | 1,008 | 29 |
| Change in fair value of derivative liabilities | 2,427 | 14,316 |
| Amortization of debt discount and finance fees | 18,182 | 29,927 |
| Stock-based compensation | 134,318 | 583,899 |
| Interest payments on convertible notes accounted for at fair value | -27,480 | -60,377 |
| Change in fair value of convertible notes | -64,369 | 121,451 |
| Prepaid expenses and other current assets | 880,497 | - |
| Accounts payable and accrued expenses | 331,198 | 545,099 |
| Prepaid expenses | - | 83,472 |
| Accrued interest payable - related parties | -590 | -1,195 |
| Change in operating lease asset and liabilities | -905 | -650 |
| Repayment of note payable-related party | - | 124,944 |
| Net cash used in operating activities | -2,626,654 | -5,881,979 |
| Payment of convertible note payable | 0 | 0 |
| Repayment of note payable-related party | -190,270 | - |
| Proceeds from exercise of pre-funded warrants | - | 19,652 |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 322,501 | 0 | 5,409,673 |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 170,000 | 0 | 4,080,000 |
| Payment of other issuance costs for issuance of common stock and equity-classified warrants | 31,199 | 526,460 |
| Proceeds from exercise of pre-funded warrants | 19,802 | - |
| Payment for finance costs | 0 | 78,414 |
| Net cash provided by (used in) financing activities | -96,375 | 8,779,507 |
| Net change in cash and cash equivalents | -2,723,029 | 2,897,528 |
| Cash and cash equivalents at beginning of period | 1,920,144 | - |
| Cash and cash equivalents at end of period | 2,094,643 | - |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)